John Poss: Fifteen years and still kickin’

By John Poss, LRG Board Member

It has been a long journey since that day Melinda and I walked out of my Dallas oncologist’s office in May, 2000 knowing that I had a rare, then untreatable cancer. Now, it has been fifteen years: years that allowed me to see the birth of grandchildren, the marriage of a daughter, the incredible growth and success of the Life Raft Group and to experience thousands of daily joys that enrich our lives. Thank you Gleevec, thank you George Demetri, thank you Life Raft Group and, most of all, thank you Melinda.

My story probably isn’t much different than the stories that

See KICKIN’ on page 8

Partnering for Cures seventh annual meeting held in NYC

By Marisa Bolognese, Deputy Executive Director

The 7th Annual Partnering for Cures meeting hosted by FasterCures was held Nov. 1-3 in NYC with more than 750 movers and shakers from patient groups, pharma, academia, government and industry. Some notable participants included: Dr. Francis Collins, NIH Director; Michael Milken, Chairman, Milken Institute; Dr. Brian Druker, OHSU Knight Cancer Center and

See PARTNERING on page 10

Adjuvant imatinib study updates results

By Pete Knox, LRG Director of Strategic Planning

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by a number of the leading European researchers in GIST, including Heikki Joensuu of Finland, Kirsten Sundby Hall of Norway, Peter Reichardt and Peter Hohenberger of Germany, and Sebastian Bauer, a member of the LRG Research Team, also from Germany, among others.

The article was a follow-up to the original study that reported a significant benefit in overall survival for three years of adjuvant treatment with 400mg imatinib versus one year (see www.liferaftgroup.org/2011/08/adjuvant-gleevec-star-of-asco/ for details)

See ADJUVANT on page 6
Today’s researchers estimate that there are over 200 classified cancers today and that one out of three people will be affected by it at some stage in their life. With the extreme prevalence of cancer in today’s world, it may be surprising to some that there is an entire category of cancers that is not only collectively rare but composed almost entirely of some of the rarest forms of cancer identified. As the most prevalent of the 70 currently classified sarcoma subtypes, GIST comprises about one third of sarcoma cases diagnosed in the United States. However, these are still extremely low figures relative to the world of cancer when you consider that sarcomas only represent 1% of all cancer diagnoses.

At the 2015 Annual Meeting of the Connective Tissue Oncology Society (CTOS), sarcoma researchers, clinicians, patient advocacy groups and the pharmaceutical industry gathered in Salt Lake City to continue the work of lifting the veil surrounding sarcomas and sarcoma research. As defined by the conference’s presenters, the largest issues currently facing soft tissue sarcoma research and treatment include:

- **Rarity of population** - With the exception of major medical centers in which specialized physicians draw patients from around the country, gathering a critical mass of patients for observation and analysis is difficult. Low patient population figures make recruitment for clinical trials difficult, and if a clinical trial cannot successfully recruit it cannot advance, limiting treatment options for the patient population in question.

- **Funding for rare orphan diseases** - Along with a smaller patient base comes the corresponding challenge of raising funding for continuing research. Private donations are less plentiful because there are simply fewer people to contribute and private industry has less of a financial incentive to invest as the target consumer base is inherently smaller. These funding challenges trickle down to researchers who struggle to keep their labs open and their work ongoing as well as impacting the number of new researchers choosing to specialize in these fields due to the lack of funding available.

- **Many distinct tumor types** - As research develops in all cancers, it is found that even though a disease may be termed with a single name (i.e. GIST), that single disease is in fact a label encompassing a host of sub-mutational types each with its own unique characteristics including progression, stability and response to treatment. In GIST alone to date...
Top GIST specialists present at California GDOL

By Mildred Menos, Strategic Alliances Director

On Sunday, November 15, the last GDOL in the 2015 series was held in Orange County, California at the Fullerton Arboretum. GDOL stands for GIST Day of Learning, a free, one-day program that provides both education and support to the GIST community. Top GIST specialists present the latest on research and treatment options as well as providing a comprehensive review of the science behind GIST. GDOLs provide an opportunity not only to meet and interact with local expert practitioners in an intimate setting, but also for patients to connect with one another in a supportive environment.

The featured speakers for this event were surgical oncologist Jason Sicklick of University of California at San Diego and medical oncologist Michael Heinrich from Oregon Health Science University. Mildred Menos, Assistant Director of Programs at the Life Raft Group, provided an overview of the LRG’s programs with a focus on the LRG Patient Registry, the impact that data donated has and the benefits its members receive. LRG Southern California state leader Dina Wiley held a support group meeting prior to the day’s seminar in which patients and caregivers could come together to provide feedback, ask questions and trade experiences about their GIST journeys.

We are currently planning the next cities for the 2016 GDOL series. Please stay tuned to the LRG website.

Society for Integrative Oncology holds 12th annual conference in Boston

By Kathryn Troy, Patient Registry Health Educator

The Society for Integrative Oncology (SIO) was developed to advance evidence based, comprehensive, integrative healthcare to improve the lives of people affected by cancer.

The 12th Annual SIO Conference was held in Boston in November, and it provided an opportunity for attendees to both be inspired by the ongoing research to improve the quality of life for cancer patients, but also to be impressed by quantitative evidence to support the research efforts and the amount of physicians more than willing to refer their patients to integrative services. The conference consisted primarily of clinicians including oncologists, nurses, and other medical doctors, followed by educators, researchers and epidemiologists as well as integrative specialists including yoga instructors, acupuncturists, reiki practitioners and, of course, patient advocates.

The conference exposed attendees to a wealth of therapies that are currently being used as part of integrative treatment including acupuncture, reiki, music therapy, and mind-body therapy, and more importantly, how each of these methods can be practiced by both patients and caregivers.

The focus for this author during the three-day conference was to learn applicable resources for GIST patients. Among the diverse research, Mind-body Therapy was of particular interest. As defined by the National Institute of Health (NIH), “Mind-body medicine focuses on the interactions among the brain, the rest of the body, the mind, and behavior as well as the ways in which emotional, mental, social, spiritual, experimental, and behavioral factors that can directly affect health.” SIO speaker Dr. Gary Deng, Ph.D., Interim Chief, Integrative Medicine Service at Memorial Sloan Kettering Cancer Center further elaborated that chang-
Genetic Alliance event invites collaboration
By Pete Knox, Strategic Planning Director

Genetic Alliance recently held an event in Chapel Hill, N.C. that brought together patient advocates, scientists and representatives from the pharmaceutical industry in a unique “speed-dating” format. Disease advocacy organizations were invited to present briefly on their opportunities for scientific collaboration, and the roadblocks to accomplishing their goals. The focus was on rare diseases and how best to approach development of therapies for them. This event was an interesting microcosm of the rare disease community with a variety of perspectives represented. Ample opportunity was provided to speak with advocates representing a broad spectrum of diseases such as Huntington’s Disease, Angioma, Adenoid Cystic Carcinoma, Autism, and others. The diseases may be disparate, but the challenges faced by rare disease advocacy organizations are similar.

Adding to this was the scientific perspective provided by the Structural Genomics Consortium, a forward-thinking research institute based out of Oxford University in the UK, Frankfurt, Germany, and UNC-Chapel Hill, N.C. Scientists at SGC-UNC are building a functional map of the genetic landscape.

October 14, 2015
Chapel Hill, N.C.

LRG’s Pete Knox with Sharon Terry, President of Genetic Alliance at the recently held event in Chapel Hill.

On the road with the LRG patient registry
By Michelle Durborow, Patient Registry Director

The tenth annual ICORD meeting was held in Mexico City on October 13-14 with the theme “A Decade of Discoveries and Current Challenges in the World of Rare Diseases and Orphan Drugs.” The meeting was part of the “Global Rare Diseases Week, Mexico 2015” and was back-to-back with the fourth Latin American meeting of Rare Diseases on October 12.

About 200 delegates from all continents and representing many different stakeholders such as patients, patient support groups, healthcare professionals, researchers, industry representatives, politicians, regulatory and health authorities came to take part in an inspiring program, to network and to share their experiences in the field of rare diseases and orphan drugs.

Michelle Durborow, LRG Director of Patient Registry presented in the session on Development and Accessibility to International Registries and Biobanks, on the importance of building a global GIST registry and tissue bank. The goal of this present-
Encouraging rare disease connections at the NORD Conference

By Erin Kristoff, Marketing Director

The National Organization for Rare Diseases (NORD) held its 2015 Breakthrough Summit October 21-22 in Arlington, Virginia. This year’s event convened top leaders from the FDA, NIH, Industry, Patient Groups, Payers and Research Institutions to address the progress of rare disease diagnosis, genomics, drug development, patient engagement, patient-centered research models, product approvals, FDA oversight and market access to orphan products.

LRG staffers Erin Kristoff and Mildred Menos were in attendance and were able to listen and engage with presenters at this innovative conference, which kicked off with an inspiring keynote address by Treacher-Collins patient advocate, Jono Lancaster.

Inspiring speeches were given by key NIH and FDA representatives including Director for the National Center for Advancing Translational Sciences (NCATS), Chris Austin and FDA’s Center for Drug Evaluation and Research Director, Janet Woodcock. Breakout sessions focused on vital issues like fueling drug access, precision medicine and patient-centered outcomes, but one of the most beneficial and thought-provoking aspects of the conference was the opportunity to make connections with other advocates in the rare disease community. Nothing can replace the help you are able to provide and gain from others facing similar challenges.

Patient-centered care focus of Quintiles panel discussion

By Mary Garland, Communications Director

Executive Director, Norman Scherzer participated in a panel discussion as part of the Executive Vision Forum Series hosted by Quintiles Advisory Services on Friday, November 6 in the Alexandria Center, NYC.

The panel, entitled “Working within a patient-centered environment: Aligning perspectives and systems to deliver value” presented views from the pharmaceutical industry, healthcare and patient advocacy. The panel included Marc Boutin, JD, CEO, National Health Council, Lorraine Marchand, Director of Healthcare and Pharmaceutical Management Program, Columbia Business School, and Norman Scherzer. Norman represented the patient view, sharing the story of the Life Raft Group, and helping the audience, which was heavily attended by pharmaceutical and healthcare industry representatives, to understand several of the key issues involved in creating more patient-centered care.

To quote Norman, “We are on the forefront of a revolution in targeted medicine, where many of the new treatments are oral drugs, versus IV chemotherapy. Compliance will play a major role in evaluating the efficacy of treatments, as it is vital to know whether or not the product is working or if the patient is not taking the medication.”

Another key point made by Scherzer was that the LRG has a model for tracking patient data and the patient perspective. The LRG Patient Registry and Tissue Bank provide a blueprint for patient-centered care, and an ideal environment to recruit patients for clinical trials.

Follow-up meetings to share the LRG model will be forthcoming.
Michael Montemurro, president of the SAKK project group gastrointestinal cancer, and a member of the GIST Award Committee.

and ultimately led to the FDA approving three years of adjuvant imatinib for advanced GIST patients.

The initial study included 400 patients with categorized by high-risk (either one of the following):

1. Largest tumor diameter is over 10cm
2. Mitosis count is over 10/50 high power microscopic fields (HPF)
3. Largest tumor diameter over 5cm the mitosis count is over 5/50 HPF

KIT-positive GIST that had successful surgery between 2004 and 2008. After surgery, patients were randomly assigned to one of two arms, and received either one year or three years of imatinib.

The follow up study, “Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk for recurrence,” had the group vs. 91.9% in the three-year group. Both of these comparisons proved to be statistically significant (p<.001 and p=.036 respectively).

While confirmation of the benefits of three years of adjuvant imatinib is an important finding, a few other questions persist that may warrant further investigation. I asked the primary author of the study, Dr. Heikki Joensuu to respond to these questions.

First, this study looked exclusively at high-risk patients. What do those findings mean to those patients in an intermediate risk category? Dr. Joensuu responded by stating, “The trial was carried out in the high-risk patient population, and the results cannot be applied to lower risk GISTs. In fact, the subgroup analyses, though limited in power, suggest that patients with GIST with a high mitotic count are the ones who benefit from three-year adjuvant imatinib, whereas

The 2015 science prize, worth CHF 10,000 and donated by GIST Group Switzerland, was presented by Dr. Michael Montemurro, president of the SAKK project group gastrointestinal cancer, and a member of the GIST Award Committee.

From left to right: Dr. Michael Montemurro, Helga Meier, and Dr. Sebastian Bauer.
the patents with a low mitotic count do not.”

Dr. Joensuu adds, “The concept of ‘intermediate risk GIST’ is poorly defined. The malignancy potential of GISTs varies from virtually benign tumors to highly malignant cancers, and it is difficult to define accurately any intermediate groups in this continuum. In practice, the criteria used in the SSGXVII/AIO trial work reasonably well in patient selection for adjuvant treatment, and the prognostic heat maps may also be helpful.” The SSGXVIII/AIO (The Scandinavian Sarcoma Group XVII/Arbeitgemeinschaft Internistische Onkologie) trial assessed patients with resected high-risk tumors, as well as those with single metastases who received complete resection of the primary tumor and the metastases. Prognostic heat maps are contour maps that assess the risk of each tumor in which the color red means a high risk, and blue means a low risk.(see www.liferaftgroup.org/risk-of-recurrence-details/ for further details about heat maps).

Second, a number of patients have reached the three-year mark of imatinib treatment and are stable or NED, and are wondering whether to continue on the medication. When Dr. Joensuu was asked what his opinion was on patients continuing treatment for patients beyond the three-year mark, he responded, “The patient needs to have NED - being stable might indicate that overt metastases have been detected, which entails permanent tyrosine kinase inhibitor (TKI) therapy. Some patients who are estimated to have a high risk for GIST recurrence despite macroscopically complete surgery might benefit from adjuvant imatinib administered for longer than three years. This remains, however, a hypothesis with little evidence to support it. There may also be patients who are harmed by long treatments, such as patients who are estimated to have a high risk but who were cured by surgery. Therefore, two randomized trials that compare longer than three years of adjuvant imatinib with the standard (i.e three years of imatinib) have been launched in Europe and are accruing patients.”

Dr. Joensuu concludes, “At present, the standard duration of adjuvant imatinib is three years; longer treatments than this have unproven benefit. It is likely very important to perform imaging of the abdomen and pelvis frequently after adjuvant imatinib has been discontinued to detect recurrence early should it arise. Recurrent GIST usually responds well to re-starting of imatinib, and the risk of emergence of drug resistance is likely lower the smaller the tumor bulk. The ongoing trials testing the longer regimens are highly important to inform us about the optimal way to treat patients who have undergone surgery for high-risk GIST.”

Data from the LRG patient registry reveals high-risk patients who have progressed after stopping imatinib even beyond the three-year mark. While this is a complicated question with a number of variables from patient to patient, a study looking at patients taking imatinib for longer time periods and assessing the benefit would be very useful, in that it would help patients make a more informed decision about whether to continue treatment. We will eagerly watch as the European studies Dr. Joensuu mentions progress and report results. Until that time, the LRG maintains that consulting with a GIST specialist who is familiar with your individual risk factors and keeping apprised of the latest medical research is the best way to make an informed decision before stopping Gleevec.
many of you have to tell. The only difference, perhaps, is that my story has lasted a bit longer. I was diagnosed in May, 2000 with a tumor the size of a cantaloupe sitting on top of my stomach, a tumor that had metastasized to my liver and a few other organs. The diagnosis was followed almost immediately by surgery and the absolute worst possible conversation with my oncologist: “I’m sorry John. We couldn’t get it all. Your liver is riddled with GIST. You have one, maybe two years to live.”

I walked out of that office determined to fight. I did my homework, and through ACOR, learned of an obscure, unpublicized Phase II Clinical Trial for STI-571 at Dana Farber Cancer Institute. I self-referred and met Dr. George Demetri for the first time in July, 2000. The drug was in very short supply, largely because of its success in treating CML, so George told me to go home and wait and pray that the drug would be available in time.

By August, my tumors were growing. By September the situation was critical. I didn’t have much time remaining when I received the much awaited email from George: “John, please report to Dana Farber on October 4 to begin treatment with STI-571.” I reported to DFCI as instructed, full of hope, and at the same time, anxiety. Within 30 days my tumors began to shrink. Now, here I am fifteen years later still kicking.

That’s the short version of the story. The long version includes: two researchers having a beer at ASCO in 1999 and discussing how STI-571, a drug to treat CML, might work for GIST; a patient in Helsinki, Finland (Patient Number One) refusing to give up and convincing Novartis to create a Phase I trial with one participant; George Demetri and Chris Carley (a fellow LRG board member) calling Chris’s brother at the Wall Street Journal and convincing them to threaten Novartis with unfavorable publicity if more drug wasn’t made available for GIST; and finally, a group of highly motivated patients and caregivers forming an email list of Clinical Trial Participants (thank you Norman) that later became the Life Raft Group.

The more important story, and question, is this: What’s it been like living with GIST and Gleevec for over fifteen years?

The first five years were the toughest. No one really knew how long STI-571, later Gleevec, would work. The mortality rate among the Phase II participants was troubling. Some didn’t make it a year; others, two or three years. After five years, we had lost too many friends, too many to name but not too many to remember, especially the ones who were active in the LRG. Thus, every trip to Dana Farber was a much anticipated and much dreaded adventure. “Scanxiety” became a too frequently used word in our family vocabulary.

I remember distinctly in 2004, a little less than five years after I started taking Gleevec, learning of the death of yet another friend. The company where I worked had just been bought by a Private Equity firm and they had offered me a very good position with the new company. I looked at my options. Based on what was happening to my fellow GISTers, I had no idea how much longer the drug would work, how much longer it would be before these tumors of mine learned to resist Gleevec. Melinda and I talked about it, and I declined the job. I wanted to work less, spend more time with my family, maybe knock a few items off my bucket list and make the best of however much time I had left. Time is the only truly priceless asset. Turns out, I had a lot more time than I expected.

I also remember that first year, when everyone was concerned with side effects. I recall an LRG board meeting around 2001. We were discussing side effects such as diarrhea, nausea, fatigue, and swelling when Melinda said, “You are leaving out a very significant side effect.” We all
looked at her expectantly, waiting to hear about this heretofore unreported condition.

She slyly smiled and said, “Gleevec must make you nice, because John sure has been easier to live with since he started taking it!”

Not so surprisingly, she was correct. Cancer, and the miraculous arrival of STI-571 just in time to save me from certain death, had changed me. I won’t admit that I was suddenly nicer, but I will admit that my whole approach to life had changed, as I am sure it has changed for most of my fellow GISTers. I now take nothing for granted. I do my best to appreciate every day as a blessing, and I certainly have more empathy for others who face life threatening challenges. So, yes, I’m probably a nicer person today than I otherwise might have been. Once again, thank you Gleevec for giving me that chance.

Here’s some very important advice to GISTers: show your caregiver some very deserved and hard-earned love. Frankly, I would be dead, even with Gleevec, without Melinda. I simply cannot list the innumerable times that she has spotted some aberration in my routines and said, “You don’t look good, you need to go get a B-12 shot or go get a Procrit shot or slow down and get more sleep.” She also feeds me well. It is simply impossible to express too much gratitude to the loved ones that surround you and keep you going. It has always been my observation that cancer is harder on loved ones than it is on the patient. Remember that.

Here’s another very important piece of advice: take care of your kidneys. We already know that Gleevec is hard on our kidneys, but so are CT scans and diarrhea and the result-
all share a common goal of bringing about cures for disease, faster and more efficiently. As summed up by Mike Milken, “The spirit of the conference is to stop talking and do something... we are all here to focus on what’s important - to eliminate life-threatening diseases for the family of mankind.”

The recurring themes of the conference were Data Sharing, Collaboration and Patient Centeredness. Here are some conference takeaways:

- **On Data:** “There are eight billion mobile devices in the world – more phones than people. Many countries in developing nations have gone straight to wireless, and many of them don’t have much regulation of research and healthcare. There is a revolution in patient empowerment through health data coming and mobile data will be at the center.” (Mike Milken)

- **On Sharing Data:** “There is a need for better data-sharing infrastructure – with patients and by patients. Technical barriers to data sharing are cultural, especially among academic institutions. Medicine should be at least as good as Netflix at analyzing data for the benefit of consumers.” (Isaac Kahone)

- **On Patient Input:** “There is no substitute for patient input. It’s very different to hear from patients directly than it is to hear from translators trying to speak on their behalf. Patients must participate in all aspects of research. What we need is not just an army of patient advocates, but an army of patient scientists.” (Jeffrey Shuren)

- **On Research Collaboration:** The Precision Medicine Initiative (which will collect health data from one million participants) presents a unique opportunity, given the confluence of the genomic revolution, the growing ability to track our health, increasing public interest in participation and partnership in research and more appetite for collaboration. Francis Collins hopes the “big, hairy audacious goal” of the PMI will inspire researchers and other stakeholders to be involved. Adding that “you can’t herd cats, but you can move their food,” referring to the incentives created by new NIH funding and the requirements that will come with it.

   Reminding the attendees of the role they play to question and change the status quo, the final session concluded with the inspiring words of anthropologist Margaret Mead, “Never doubt that a small group of thoughtful, committed citizens can change the world: indeed, it’s the only thing that does.” Will Reeve echoed this sentiment in recalling his father’s certainty that a cure for spinal cord injuries could be found: “At first your dreams are impossible, and then they are improbable and finally, when you summon the will they become inevitable.” Words to live by and very much seconded by the Life Raft Group as we continue in our tireless search to find a cure for GIST.

To hear more from the speakers and read about all the sessions at Partnering for Cures check out these links:

See videos from all the sessions on Partnering for Cures 2015

You Tube: www.youtube.com/user/FasterCures

Tumblr link with recaps of all the sessions: www.fastercures.tumblr.com

Twitter link: www.twitter.com/hashtag/fcp4c

The Power of Ideas www.milkeninstitute.org/issues/power-of-ideas

Marisa Bolognese (left), and Sara Rothschild (right) with Dr. Brian Druker.
ing the body from the outside (through guided therapy, breathing exercises, etc.) can stimulate cell changes, and ultimately reduce side effects such as anxiety, depression, digestive problems, health issues, and fatigue. Additionally, Dr. Deng spoke of the immense value in educating clinicians, and encouraged specialists to seek hospital based educational programs so that each oncologist can refer and practice integrative services to improve the patient’s overall quality of care.

Moving forward, the SIO admitted that although they have made great progress in instituting and educating integrative practices in oncology care, there is still work to be done. They have made great headway in raising networks of integrative oncology services at cancer centers both nationally and internationally, so that outpatient clinics can provide free services to their patients affording them the ability to conveniently engage in the best of what western and integrative medicine has to offer. Additionally, guidelines are in development to identify the ways to measure patient needs, so that they can have individualized feedback to improve their health and treatment outcomes.

Overall, it was clear the various practices of integrative oncology have an evidence-based record in reducing major side effects, and even reducing the risks of some cancers recurrence, simply through routine mindfulness. For caregivers, active mindfulness affords the ability to start each day fresh, rejuvenated, and able to prioritize their task-list. For patients, it’s an opportunity to help play a role in preventative health practices, and take an active role in improving their quality of life. As the field of integrative oncology expands, it will be exciting to see specific research into the role of integrative therapies in the treatment of GIST.

**CALANDER OF EVENTS**

**MAY 12, 2016**
**Water of Life 2016**
Midtown Loft, New York, New York
5:00 PM - 11:30 PM
www.lrgwateroflife.org

**JANUARY 28, 2016**
**CancerCare Workshop**
Living with Gastrointestinal Stromal Tumors (GIST)
www.liferaftgroup.org/events/cancercare-workshop

**JULY 15-17, 2016**
**Life Fest 2016**
Torrance Marriott Redondo Beach
3635 Fashion Way
Torrance, CA 90503
www.liferaftgroup.org/lifefest

**SIO from page 3**

If you have a Cancerversary, let us know. Contact us at info@liferaftgroup.org and we may feature you in a future newsletter!
tation was to raise awareness about GIST as a rare disease, to highlight the power of patient data and tissues in the research for treatments and to demonstrate how data can fill the gaps in understanding GIST. The other speakers in this session were Yaffa Rubinstein (NIH, USA), who presented about the NIH/NCATS GRDR® Program (Global Rare Diseases Patient Registry Data Repository) who spoke about linking patient registries data to bio-specimens data and Manuel Posada (Instituto de Salud Carlos III, Spain), whose topic was medical ontologies and registering activities, what are their added values?

**GIST Day of Learning at LRG Canada**

GIST Sarcoma Life Raft Group Canada held its fourth GIST Day of Learning on Oct. 24, 2015 in Ottawa, Ontario. The event brought together patients, caregivers, advocates and researchers for a day of sharing valuable information, expertise and tools to support patients with GIST. Michelle Durborow, LRG Patient Registry Director was one of the speakers at this event, presenting about the how GIST patients, physicians and researchers can mutually benefit from the data gathered in the patient registry. The presentation entitled “The LRG Patient Registry: Research, Education and Support in Practice” illustrated the history of the registry and tissue bank and focused on practical examples of how patients can learn from the data to guide them in making informed decisions together with their physicians about their care.

**SPAEN Annual Conference**

Sarcoma Patients EuroNet held its sixth Annual Conference for Organizations Representing Patients with Sarcomas, GIST and Desmoid Tumors on November 19-21, 2015.

Below: SPAEN annual conference brought together an international group of sarcoma patients advocates, leading experts, and pharmaceutical representatives in Chantilly, France.
in Chantilly, France. The three-day conference was focused on research, treatment and access to treatment and advocacy/capacity building. Participants were sarcoma patient advocates and leading experts from different countries as well as pharmaceutical representatives who shared best practice examples, research updates and treatment options. Michelle Durborow, LRG Patient Registry Director, presented the survey tools and data collection to develop programs tailored to patients’ needs in terms of information on the possible impact of the generic versions of imatinib. This presentation was a follow-up from the Generic Task Force meeting that occurred in July, 2015 in Munich Germany.

Dr. Anette Duensing, Michelle Durborow, and Dr. Sebastian Bauer

understudied protein kinases in human biology and diseases through open sharing of compounds with the scientific community. They are developing a hub for kinase drug discovery.

Representatives from a number of pharmaceutical companies and patient advocacy organizations such as the LRG explored opportunities for collaborations which may lead to future conversations as the LRG explores avenues to aid in our research.

A number of presentations by other rare disease advocacy organizations were given at the event, with the opportunity for a presentation on how the LRG and its research team are tackling the problem of Gleevec resistance, and the roadblocks we need to overcome to solve this.

While only a one-day event with a specific focus, the concept of creating opportunities for patient advocacy organizations, the scientific community and pharma holds promise for future innovation through collaborative efforts.
there are 14 classified mutational types, with many more still unknown and grouped together as “wildtype”. With this level of variability existing within even a single disease, tackling the complexity of sarcomas is daunting.

Initial diagnosis and treatment -
Since sarcomas present in such a rare and varied manner, a patient’s first diagnosis and treatment will almost invariably be by a non-specialist. There are few true practicing sarcoma specialist clinicians and those in the United States tend to be clustered along the coasts making regular travel and access difficult for patients. Some GIST patients are referred to gastrointestinal specialists instead of oncologists and not all oncologists are familiar with GIST, let alone the rarer sarcomas.

Treatment of metastatic disease
- For those sarcomas, like GIST, which do not manifest physical symptoms unique to one condition or if there is a delay in visible symptoms until the cancer is at an advanced stage, the incidence of metastatic disease at diagnosis is a clear danger. Greater funding for research, better physician education and awareness, and improved screening techniques can all contribute to the decrease of metastatic disease progression. However, treating metastatic disease may be inevitable in some cases leading to a difficult set of challenges. A tumor’s location, size and mutational type each inform the course of treatment. Weighing multiple sets of factors expands the decision criteria considerably and leaves the treating physician with a series of difficult decisions.

In addition to acknowledging and delving into the challenges facing the sarcoma community, CTOS also provided an opportunity to present the future goals of research in the coming years and the direction and focus needed to improve patient outcomes:

- Better understanding of biology
- Better understanding of pathogenetic mechanisms
- Larger collaborative studies of single histotypes
- Prognostic schemes of individual histotypes
- More targeted therapies
- Affordable, effective care

Although there is clearly much work still to be done, the field of GIST research and its patients have benefitted from many significant breakthroughs in the origins and understanding of GIST mutations and the treatment options these have yielded including three FDA-approved oral chemotherapies. The road for many other sarcomas has been longer and much more difficult with some still searching for answers as to the cause of their cancer. CTOS 2015 provided an opportunity for the rarest of the cancer world to unite over not only their collective challenges but also the areas in which they might collaborate to improve the lives of those with sarcoma as a whole.

A Memorial Talk was held on Saturday, November 14 at the Kingdom Hall of Jehovah’s Witnesses, 223 Cherry Lane, Airmont, NY 10952.
I met Ian Rahimi today.

I knew that going to his funeral would give me an opportunity to pay my respects to Ian and his family and to mourn his passing.

I knew that this would be a very emotional experience and that the fact this was a 19 year old would be particularly compelling.

I knew that the connection to GIST would add another chapter to the many patients we have lost and whose funerals or memorials I had attended.

When Franko, Ian’s father, took the podium I began to realize that up to now I had only really known about Ian the patient, a brave patient to be sure, but a struggling patient going in and out of hospitals and living for the last few months in an ICU bed in a NYC hospital. There was the extra irony that my wife Anita had just been a patient in the very same hospital separated from Ian by only a few floors.

Then Franko began to speak. About a brilliant young scientist who had one of those million-to-one brains that could figure out extraordinary complex scientific problems at the level of advanced physicists way beyond his years. About a self-effacing personality and a unique ability to put others at ease as he helped them. About a less than superb athlete who embraced soccer with a zeal to help his team and an early understanding about the brotherhood of young men.

Then brother Andrew took the podium. I learned about how Ian could never figure out how not to tell the truth and how he helped everyone solve problems, including their homework—except not his sister’s. Because he realized that there was something special about her that could only be nurtured by making her figure it out on her own.

Up came Sister Rebecca who told about a practical joker whose caring for others created such affection back to him and whose brilliance of mind was tempered by not wanting people like me to talk about him.

Finally, if there was not a single emotion in my body that had not yet been stretched to the limit, up to the podium came Katie. They met years ago in school, attended each other’s proms (he turned her down the first time she asked him to attend hers because he did not think she was serious; but she asked again). They became friends. And then they fell in love. Most people spend their lives looking for their soulmate but Katie and Ian found each other when they were teenagers. Maybe this was God’s way of showing them something so early because it would be cut off so soon.

I met Ian Rahimi today and I fell in love with him and everything he stood for.

Norman J. Scherzer
Executive Director
The Life Raft Group

Donations may be made to:

For Ian GIST FUND
Michael Hibler
Johns Hopkins University
750 East Pratt Street, Suite 1700
Baltimore, MD 21202
410-361-6189
# THE LIFE RAFT GROUP

## LRG STAFF
- **Executive Director:** Norman Scherzer
- **Deputy Executive Director:** Marisa Bolognesi
- **Patient Registry Director:** Michelle Durborow
- **Communications Director:** Mary Garland
- **Strategic Planning Director:** Pete Knox
- **Marketing Director:** Erin Kristoff
- **Strategic Alliances Director:** Mildred Menos
- **Development Director:** Sara Rothschidld
- **Senior Patient Registry Associate:** Kathrena Aljallad
- **IT & Design Manager:** Matthew Mattioli
- **Office Manager:** Jessica Nowak
- **Patient Registry Health Educator:** Kathryn Troy
- **Website Manager:** Thomas Cordasco
- **Administrative Services Associate:** Angela Edison
- **Development Manager:** Christine Incontro
- **Patient Registry Associate:** Josette Pierre
- **Finance Director:** Lorraine Ramadan

## LRG VOLUNTEERS
- **Pediatric GIST:** erin MacLean
- **Official Greeter:** Gail Mansfield
- **Latin America Liaison:** Vicky Ossio
- **Clinical Trials Coordinator:** Jim Hughes
- **Photographer:** Kim Tallau
- **Special Projects Asst.: Science Team:** Eileen Glasser
- **Tanya DeSanto:** Jim Hughes
- **David Josephy:** Michael Josephy
- **Rick Ware:** Glenn Wishon
- **Paula Vetel:**

### Consultants
- Piga Fernandez, James Lee, Kathleen Gronet

## BOARD OF DIRECTORS
- **Executive Committee:**
  - Jerry Cudził — President
  - Stan Bunn — Past President
  - Gary Glasser — Secretary/Treasurer
- **Mia Byrne:**
- **Chris Carley:**
- **Jim Hughes:**
- **Jerry Knapp:**
- **John Poss:**
- **Rodrigo Salas:**
- **Larry Selkovits:**
- **Ray Montague (Ex Officio):**

## THE LIFE RAFT GROUP

### Life Raft regional chapters: Find your reps info at liferaftgroup.org/find-a-support-group/

<table>
<thead>
<tr>
<th>State</th>
<th>Rep Name</th>
<th>Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arizona</td>
<td>Ellen MacDonald</td>
<td>Arizona</td>
</tr>
<tr>
<td>California</td>
<td>Martha Zielinski</td>
<td>California</td>
</tr>
<tr>
<td>Colorado</td>
<td>Susy Clough</td>
<td>Colorado</td>
</tr>
<tr>
<td>Delaware</td>
<td>Cindy Bones</td>
<td>Delaware</td>
</tr>
<tr>
<td>Florida</td>
<td>Jeff Davis</td>
<td>Florida</td>
</tr>
<tr>
<td>Georgia</td>
<td>Barbara Auw</td>
<td>Georgia</td>
</tr>
<tr>
<td>Idaho</td>
<td>Janet Conley</td>
<td>Idaho</td>
</tr>
<tr>
<td>Illinois</td>
<td>Jim Hughes</td>
<td>Illinois</td>
</tr>
<tr>
<td>Iowa</td>
<td>Marlene Ne</td>
<td>Iowa</td>
</tr>
<tr>
<td>Kentucky</td>
<td>Cindy Betz</td>
<td>Kentucky</td>
</tr>
<tr>
<td>Louisiana</td>
<td>Jodi Merry</td>
<td>Louisiana</td>
</tr>
<tr>
<td>Maine</td>
<td>Charles Burke</td>
<td>Maine</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>Ellen Rosenthal</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>Michigan</td>
<td>Cliff Kopp</td>
<td>Michigan</td>
</tr>
<tr>
<td>Missouri</td>
<td>Katie Bloss</td>
<td>Missouri</td>
</tr>
<tr>
<td>Montana</td>
<td>Dirk Niebaum</td>
<td>Montana</td>
</tr>
<tr>
<td>Nevada</td>
<td>Joan Smith</td>
<td>Nevada</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>Julie Thorne</td>
<td>New Hampshire</td>
</tr>
<tr>
<td>New Jersey</td>
<td>Anita Getler</td>
<td>New Jersey</td>
</tr>
<tr>
<td>New York</td>
<td>Pat Bonda Swenson</td>
<td>New York</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>Jane Rowan</td>
<td>Oklahoma</td>
</tr>
</tbody>
</table>

### Life Raft country liaisons: Learn more about the Global GIST Network & find contact info for your rep at www.globalgistnetwork.com

<table>
<thead>
<tr>
<th>Country</th>
<th>Rep Name</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>Sandra Mesri</td>
<td></td>
</tr>
<tr>
<td>Australia</td>
<td>Roy Neil</td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>Amy Bruno-Lindner</td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>Gerard van Oortmerssen</td>
<td></td>
</tr>
<tr>
<td>Bolivia</td>
<td>Virginia Ossio</td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Valeria Hart</td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Juliana Popova</td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>David Josephy</td>
<td></td>
</tr>
<tr>
<td>Chile</td>
<td>Pita Fernández</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>Zee Zee Zhenxi Zhong</td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>Maria Helena Matamala</td>
<td></td>
</tr>
<tr>
<td>Costa Rica</td>
<td>Michael Josephy</td>
<td></td>
</tr>
<tr>
<td>Cyprus</td>
<td>George Constantinou</td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>Jana Pelouchová</td>
<td></td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>Alejandro Miranda</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>Marjo Vaisanen</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>Estelle LeCointe</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>Markus Wartenberg</td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>Letiferis Patapis</td>
<td></td>
</tr>
<tr>
<td>Guatemala</td>
<td>Silvia Castillo de Armas</td>
<td></td>
</tr>
<tr>
<td>Honduras</td>
<td>Xiomara Barrientos</td>
<td></td>
</tr>
<tr>
<td>Hungary</td>
<td>Tünde Kazdta</td>
<td></td>
</tr>
<tr>
<td>India</td>
<td>Nikhil Guhagarak</td>
<td></td>
</tr>
<tr>
<td>Iran</td>
<td>Negar Amirfarhad</td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>Carol Jones</td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>Avi Zigdon</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>Gabriella Tedone</td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>Sumito Nishidate</td>
<td></td>
</tr>
<tr>
<td>Jordan</td>
<td>Sameer Yaser</td>
<td></td>
</tr>
<tr>
<td>Kenya</td>
<td>Fenindan Mwanga</td>
<td></td>
</tr>
<tr>
<td>South Korea</td>
<td>Hyun Jung Yang</td>
<td></td>
</tr>
<tr>
<td>Macedonia</td>
<td>Dejan Krstevski</td>
<td></td>
</tr>
<tr>
<td>Malaysia</td>
<td>Choo Sian Yong</td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Rodrigo Salas</td>
<td></td>
</tr>
<tr>
<td>Namibia</td>
<td>Lon Garber</td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td>Gerard van Oortmerssen</td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td>Joy Rycroft</td>
<td></td>
</tr>
<tr>
<td>Nicaragua</td>
<td>Maria Teresa Ponce</td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>Frode Hond</td>
<td></td>
</tr>
<tr>
<td>Pakistan</td>
<td>Muhammad Shahid Rafique</td>
<td></td>
</tr>
<tr>
<td>Peru</td>
<td>Eva Maria Ruiz</td>
<td></td>
</tr>
<tr>
<td>Philippines</td>
<td>Rod Padua</td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>Piotr Fonrobert</td>
<td></td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>Eileen Rolon</td>
<td></td>
</tr>
<tr>
<td>Romania</td>
<td>Simona Ene</td>
<td></td>
</tr>
<tr>
<td>Russia</td>
<td>Tanya Soldak</td>
<td></td>
</tr>
<tr>
<td>Samoa</td>
<td>Leasi John Galuva</td>
<td></td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>Mohamed-Elbagir Ahmed</td>
<td></td>
</tr>
<tr>
<td>Scotland</td>
<td>Stacey McAuliy</td>
<td></td>
</tr>
<tr>
<td>Singapore</td>
<td>Kie Go</td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>Annette Mentasti</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>Luis Herrero</td>
<td></td>
</tr>
<tr>
<td>Sudan</td>
<td>Mohamed-Elbagir Ahmed</td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>Heiga Schnurf</td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>Kittikir Pomppakakul</td>
<td></td>
</tr>
<tr>
<td>Turkey</td>
<td>Haver Tanbay</td>
<td></td>
</tr>
<tr>
<td>Ukraine</td>
<td>Larisa Kuvlenko</td>
<td></td>
</tr>
<tr>
<td>U.K.</td>
<td>Nicola Wardle</td>
<td></td>
</tr>
<tr>
<td>Uruguay</td>
<td>Fabrizio Martiotta</td>
<td></td>
</tr>
<tr>
<td>Venezuela</td>
<td>Maria Isabel Gómez</td>
<td></td>
</tr>
</tbody>
</table>

## Additional Information
- **Facebook:** facebook.com/liferaftgroup
- **Twitter:** twitter.com/liferaftgroup
- **LinkedIn:** http://linkd.in/liferaftgroup
- **YouTube:** http://www.youtube.com/LifeRaftGroup

## Contact Information
- **155 US Highway 46, Suite 202**
- **Wayne, NJ 07470**
- **p:** 973-837-9092
- **f:** 973-837-9095
- **e:** liferaft@liferaftgroup.org
- **w:** www.liferaftgroup.org